DK3609497T3 - Niraparib, abirateronacetat og prednison til behandling af prostatakræft - Google Patents

Niraparib, abirateronacetat og prednison til behandling af prostatakræft Download PDF

Info

Publication number
DK3609497T3
DK3609497T3 DK18720895.4T DK18720895T DK3609497T3 DK 3609497 T3 DK3609497 T3 DK 3609497T3 DK 18720895 T DK18720895 T DK 18720895T DK 3609497 T3 DK3609497 T3 DK 3609497T3
Authority
DK
Denmark
Prior art keywords
niraparib
prednisone
treatment
prostate cancer
abirateron
Prior art date
Application number
DK18720895.4T
Other languages
English (en)
Inventor
Margaret K Yu
Linda Anne Snyder
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3609497(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK3609497T3 publication Critical patent/DK3609497T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DK18720895.4T 2017-04-13 2018-04-09 Niraparib, abirateronacetat og prednison til behandling af prostatakræft DK3609497T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13
PCT/US2018/026661 WO2018191141A1 (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Publications (1)

Publication Number Publication Date
DK3609497T3 true DK3609497T3 (da) 2022-10-31

Family

ID=62067858

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18720895.4T DK3609497T3 (da) 2017-04-13 2018-04-09 Niraparib, abirateronacetat og prednison til behandling af prostatakræft

Country Status (33)

Country Link
US (4) US20180296574A1 (da)
EP (3) EP4176878A1 (da)
JP (3) JP7141408B2 (da)
KR (1) KR20190134718A (da)
CN (2) CN110753545A (da)
AU (2) AU2018251594A1 (da)
CA (1) CA3059562A1 (da)
CL (1) CL2019002871A1 (da)
CO (1) CO2019011591A2 (da)
CR (1) CR20190467A (da)
DK (1) DK3609497T3 (da)
DO (1) DOP2019000264A (da)
EA (1) EA201992430A1 (da)
ES (1) ES2931052T3 (da)
HR (1) HRP20221327T1 (da)
HU (1) HUE060460T2 (da)
IL (2) IL320452A (da)
JO (2) JOP20190244B1 (da)
LT (1) LT3609497T (da)
MA (1) MA48728B1 (da)
MD (1) MD3609497T2 (da)
MX (2) MX2019012296A (da)
MY (1) MY209010A (da)
NI (1) NI201900105A (da)
PE (1) PE20200444A1 (da)
PH (1) PH12019502317A1 (da)
PL (1) PL3609497T3 (da)
PT (1) PT3609497T (da)
RS (1) RS63832B1 (da)
SG (1) SG11201909552VA (da)
SM (1) SMT202200467T1 (da)
UA (1) UA129514C2 (da)
WO (1) WO2018191141A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
WO2020139339A1 (en) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
CN110538150A (zh) 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
UY39201A (es) * 2020-05-08 2021-11-30 Janssen Pharmaceutica Nv Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib
BR112023018906A2 (pt) * 2021-03-24 2023-10-10 Astellas Pharma Inc Combinação de talazoparib e um antiandrógeno para o tratamento de câncer de próstata metastático sensível à castração com mutação no gene ddr
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
JP7320903B2 (ja) 2021-12-15 2023-08-04 湖南慧▲澤▼生物医▲薬▼科技有限公司 アビラテロン酢酸エステルを含む組成物及び使用
WO2023194525A1 (en) * 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法
CN121443291A (zh) * 2023-08-02 2026-01-30 詹森药业有限公司 尼拉帕尼和阿比特龙组合用于治疗转移性去势抵抗性前列腺癌

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3804730A1 (en) * 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
JP5989965B2 (ja) 2008-01-08 2016-09-07 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (en) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use

Also Published As

Publication number Publication date
US20240245710A1 (en) 2024-07-25
SMT202200467T1 (it) 2023-01-13
EP3609497B1 (en) 2022-10-12
MD3609497T2 (ro) 2023-03-31
EA201992430A1 (ru) 2020-02-28
PE20200444A1 (es) 2020-02-28
JOP20190244B1 (ar) 2024-04-18
EP3609497A1 (en) 2020-02-19
HRP20221327T1 (hr) 2023-03-17
HUE060460T2 (hu) 2023-03-28
IL320452A (en) 2025-06-01
EP4176879A1 (en) 2023-05-10
UA129514C2 (uk) 2025-05-21
IL269879A (da) 2019-11-28
CA3059562A1 (en) 2018-10-18
PL3609497T3 (pl) 2023-01-23
CR20190467A (es) 2020-03-09
JP2020516646A (ja) 2020-06-11
US20220175801A1 (en) 2022-06-09
SG11201909552VA (en) 2019-11-28
MX2019012296A (es) 2019-11-28
MA48728A (fr) 2020-04-08
DOP2019000264A (es) 2020-07-15
CO2019011591A2 (es) 2020-02-28
AU2024202346A1 (en) 2024-05-02
NI201900105A (es) 2020-03-11
JP7407880B2 (ja) 2024-01-04
ES2931052T3 (es) 2022-12-23
LT3609497T (lt) 2022-12-12
IL269879B1 (en) 2025-06-01
EP4176878A1 (en) 2023-05-10
JOP20190244A1 (ar) 2019-10-13
MY209010A (en) 2025-06-16
AU2024202346B2 (en) 2026-01-22
CN110753545A (zh) 2020-02-04
KR20190134718A (ko) 2019-12-04
US20180296574A1 (en) 2018-10-18
MX2023009569A (es) 2023-08-22
BR112019021466A2 (pt) 2020-05-12
JP2022141881A (ja) 2022-09-29
JP2024023344A (ja) 2024-02-21
JP7141408B2 (ja) 2022-09-22
WO2018191141A1 (en) 2018-10-18
AU2018251594A1 (en) 2019-10-24
CN119235874A (zh) 2025-01-03
PH12019502317A1 (en) 2020-07-06
PT3609497T (pt) 2023-01-23
MA48728B1 (fr) 2022-10-31
RS63832B1 (sr) 2023-01-31
CL2019002871A1 (es) 2019-12-27
JOP20230159A1 (ar) 2023-07-13
US20240398837A1 (en) 2024-12-05
IL269879B2 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
DK3609497T3 (da) Niraparib, abirateronacetat og prednison til behandling af prostatakræft
IL269150A (en) Compositions and methods for treating cancer
IL268814A (en) Compositions and methods for treatment of cancer
IL258955A (en) Compositions and methods for treatment of cancer
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
IL263224A (en) Methods and compositions for treating cancers
DK3826667T3 (da) Claudin6-antistoffer og fremgangsmåder til behandling af kræft
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
DK3294770T3 (da) Terapeutiske og diagnostiske fremgangsmåder til cancer
IL258378A (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
IL273919A (en) Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
DK3778592T3 (da) PSMA-målrettet radiolægemiddel til diagnosticering og behandling af prostatacancer
DK3380495T3 (da) Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi
IL269157A (en) Compositions and methods for treating cancer
IL265697B1 (en) Treatment of prostate cancer
IL264443A (en) Methods of treating prostate cancer
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK3755816T3 (da) Fremgangsmåder til påvisning og behandling af prostatacancer
DK3576740T3 (da) Cancerbehandling
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
DK3638293T3 (da) Sammensætninger til behandling af cancer
IL308399A (en) Methods of treating cancer
IL281600A (en) Methods of treating cancer
IL281845A (en) Combination therapy for the treatment of cancer